All cellular components of the eTEM assay, 3B-11 endothelial cells, Met-1 and E0771 tumor cells, as well as BMDMs, expressed CXCR2 (Figure 4E), indicating that the reduction in tumor cell transendothelial migration observed with pharmacological inhibition of CXCR2 was not necessarily a result of specific inhibition of macrophages. This evidence concerns the gene CXCR2 and neoplasm.